Standard BioTools Inc. (LAB) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, LAB scores 27 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 3 of 20, reflecting ROIC of -28.7% and an FCF yield of 0%; for a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support its valuation. The Whale 13F Flow pillar scores 8 of 20 for institutional accumulation and options positioning, indicating limited institutional support in the source data. The Insider Conviction pillar scores 5 of 20 based on SEC Form 4 and Congressional PTR cluster flow. The Macro Regime Fit pillar scores 6 of 20, with beta of 1.0 and sector sensitivity noted. The Forensic Balance Sheet pillar scores 5 of 20, with Altman Z of 0.2, Piotroski F of 4/9, and Debt/Equity of 0.5, all pointing to elevated distress risk. Taken together, the rating frames the stock as a forensic-risk name where the upside case depends on a turnaround that the current cash-generation and balance-sheet metrics do not yet demonstrate. Valuation multiples such as P/E are not available in source data, so the tradeoff between price and earnings power cannot be assessed from the sources provided.

Standard BioTools Inc. (LAB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry, per the company profile. Per the recent news wire, the company has announced an agreement to sell its Microfluidics business to ARCHIMED. Revenue for FY 2025 was $85.3M per the SEC financials. Specific details on customers and monetization beyond the sector and industry classification are not available in source data.

Per the SEC financials, revenue declined from $106.3M in FY 2023 to $91.0M in FY 2024 and $85.3M in FY 2025, while operating losses persisted in each reported year. Per the market data, gross margin is 49.9%, while operating and net margins are each -60%, and ROIC is -28.7%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9, both consistent with forensic distress signals; Debt/Equity is 0.5 per the same rating. Cash declined from $166.7M to $120.9M between FY 2024 and FY 2025.

Per the recent news wire, the dominant catalyst is the agreement to sell the Microfluidics business to ARCHIMED, reported across multiple outlets. A second item covers a proposed 1-for-20 to 1-for-40 reverse split tied to a Treeline merger, per Stock Titan. All news items carry a YELLOW light and MARKET WIRE impact label. The Butterfly Supply-Chain Graph shows no supply-chain linkages and no proprietary signals. Watch items include execution on the divestiture, the reverse-split and merger terms, and the cash position relative to continued operating losses.

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE with no butterfly links, so upstream and downstream dependencies cannot be mapped from the source data. The sector classification of Health Care and industry of Laboratory Analytical Instruments is the only sector context provided. The proposed reverse split and the Microfluidics divestiture are the primary second-order events an investor should track, since they may alter share structure and the revenue base, though the source data does not quantify either effect.

• What price and share-count effects will the proposed reverse split and Treeline merger have, and what are their terms?
• What revenue and cash-flow contribution does the Microfluidics business make, and how will the proceeds be used?
• What is the debt structure, given that debt fields are N/A in the SEC financials despite a Debt/Equity of 0.5 in the RQD rating?
• Why are EPS and valuation multiples unavailable, and what is the earnings trajectory?
• Who are the institutional and insider holders, and are there any current analyst estimates?